These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35153191)

  • 21. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
    Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
    Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF
    van Breeschoten J; Wouters MWJM; Hilarius DL; Haanen JB; Blank CU; Aarts MJB; van den Berkmortel FWPJ; de Groot JB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Blokx WAM; Tije BJT; Veldt AAMV; Vreugdenhil A; Boers-Sonderen MJ; van den Eertwegh AJM
    Br J Cancer; 2021 Mar; 124(7):1222-1230. PubMed ID: 33495600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma.
    Kakadia S; Yarlagadda N; Awad R; Kundranda M; Niu J; Naraev B; Mina L; Dragovich T; Gimbel M; Mahmoud F
    Onco Targets Ther; 2018; 11():7095-7107. PubMed ID: 30410366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition.
    Buchbinder EI; Giobbie-Hurder A; Ott PA
    Invest New Drugs; 2023 Jun; 41(3):365-370. PubMed ID: 37097370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanoma.
    Poizeau F; Balusson F; Lemaitre F; Tron C; Pracht M; Russo D; Dinulescu M; Lesimple T; Oger E; Dupuy A
    Br J Dermatol; 2023 Mar; 188(4):482-490. PubMed ID: 36760148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis.
    Pala L; De Pas T; Pagan E; Minucci S; Catania C; Digiacomo N; Cocorocchio E; Laszlo D; Di Muzio A; Barigazzi C; Stucchi E; De Grandi L; Stucchi S; Viale G; Gelber RD; Bagnardi V; Conforti F
    Semin Oncol; 2023; 50(1-2):34-39. PubMed ID: 36967333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.
    Russo I; Zorzetto L; Frigo AC; Chiarion Sileni V; Alaibac M
    Eur J Dermatol; 2017 Oct; 27(5):482-486. PubMed ID: 29084636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis.
    De Meza MM; Blokx WAM; Bonenkamp JJ; Blank CU; Aarts MJB; van den Berkmortel FWPJ; Boers-Sonderen MJ; De Groot JWB; Haanen JBAG; Hospers GAP; Kapiteijn E; Van Not OJ; Piersma D; Van Rijn RS; Stevense-den Boer M; Van der Veldt AAM; Vreugdenhil G; Van den Eertwegh AJM; Suijkerbuijk KPM; Wouters MWJM
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma.
    Khaddour K; Johanns TM; Ansstas G
    Melanoma Manag; 2021 Feb; 8(2):MMT55. PubMed ID: 34084449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
    Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB
    ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive
    Rossi E; Schinzari G; Cellini F; Balducci M; Pasqualoni M; Maiorano BA; Fionda B; Longo S; Deodato F; Di Stefani A; Peris K; Gambacorta MA; Tortora G
    Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.
    Amann VC; Hoffmann D; Mangana J; Dummer R; Goldinger SM
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1638-1640. PubMed ID: 28401596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
    Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
    Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside.
    Fujimura T; Fujisawa Y; Kambayashi Y; Aiba S
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31514399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Impact of Drug-Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma.
    Mezi S; Botticelli A; Scagnoli S; Pomati G; Fiscon G; De Galitiis F; Di Pietro FR; Verkhovskaia S; Amirhassankhani S; Pisegna S; Gentile G; Simmaco M; Gohlke B; Preissner R; Marchetti P
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis.
    Mincu RI; Mahabadi AA; Michel L; Mrotzek SM; Schadendorf D; Rassaf T; Totzeck M
    JAMA Netw Open; 2019 Aug; 2(8):e198890. PubMed ID: 31397860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors.
    Awada G; Schwarze JK; Tijtgat J; Fasolino G; Kruse V; Neyns B
    Melanoma Res; 2022 Jun; 32(3):183-191. PubMed ID: 35377866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
    Rose AAN
    Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF and MEK inhibition in melanoma.
    Dossett LA; Kudchadkar RR; Zager JS
    Expert Opin Drug Saf; 2015 Apr; 14(4):559-70. PubMed ID: 25648338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.